U064 JAAD Game Changers
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
JAAD Game Changers are a selection of landmark articles that have changed the way dermatology is practiced. This forum will consist of short presentations by Game Changer article authors followed by a 15-minute interchange with the audience to ask the authors questions about their ground-breaking work. The selected top 10 Game Changers over the last 2 years of JAAD will be presented. At the end of this session, the audience will use an Audience Response System to vote for "JAAD Game Changer of the Year."
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 Continuing Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Summarize selected seminal JAAD publications of the previous 2 years.
Discuss the publications focusing on application of knowledge to the diagnosis, management, and treatment of dermatologic disease.
Promote academic interchange with the authors of selected publications to improve retention of information.
SCHEDULE
12:00 PM
Introduction
Wendi E. Wohltmann, MD, FAAD, Eden Louise Pappo Lake, MD, FAAD, Sarah Woodside, MD
12:02 PM
Most cutaneous squamous cell carcinoma recurrences occur in the first 3 years after diagnosis: A multicenter retrospective cohort study
Emily S Ruiz, MD, FAAD
12:06 PM
Reticulated livedoid skin patterns after soft-tissue filler-related vascular adverse events
leonie schelke
12:10 PM
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Brett King, MD, PhD, FAAD
12:14 PM
Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome
Milton Rodríguez-Zúñiga, MD
12:18 PM
Retrospective cohort study characterizing PD-1/PD-L1 checkpoint inhibition associated Stevens-Johnson syndrome and toxic epidermal necrolysis
Michael S. Kolodney, MD, PhD
12:22 PM
Melanoma survival by age group: Population-based disparities for adolescent and young adult patients by stage, tumor thickness, and insurance type
Katherine Wojcik
12:26 PM
Excision margins for melanoma in situ on the head and neck - A single-center 10-year retrospective review of treatment with Mohs micrographic surgery
Divya Srivastava, MD, FAAD
12:30 PM
No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and HS patients
Bella Lee
12:34 PM
Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study
Zachary A. Zinn, MD, FAAD
12:38 PM
Timing of potassium monitoring in females treated for acne with spironolactone is not optimal: A retrospective cohort study
Jenny Lai, PhD
12:42 PM
Interactive audience question & answer session with all GC authors
12:57 PM
Selection of JAAD Game Changer of the Year via ARS/Closing remarks
Wendi E. Wohltmann, MD, FAAD, Eden Louise Pappo Lake, MD, FAAD, Sarah Woodside, MD
SPEAKERS
Brett King, MD, PhD, FAAD
Michael S. Kolodney, MD, PhD
Jenny Lai, PhD
Bella Lee
Eden Louise Pappo Lake, MD, FAAD
Milton Rodríguez-Zúñiga, MD
Emily S Ruiz, MD, FAAD
leonie schelke
Divya Srivastava, MD, FAAD
Wendi E. Wohltmann, MD, FAAD
Katherine Wojcik
Sarah Woodside, MD
Zachary A. Zinn, MD, FAAD
SPEAKER DISCLOSURES
Brett King, MD, PhD, FAAD
AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Amgen – Consultant (1099 relationship)(Fees); AnaptysBio – Consultant(Fees), Investigator(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Aquestive Therapeutics – Consultant (1099 relationship)(Fees); Arena Pharmaceuticals – Consultant(Fees), Investigator(Fees); ASLAN Pharmaceuticals – Consultant (1099 relationship)(Fees), Investigator(Fees); BiologicsMD, Inc. – Consultant(Stock Options); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Eli Lilly and Company – Consultant(Fees), Investigator(Fees), Speaker(Honoraria); Equillium, Inc. – Consultant (1099 relationship)(Fees); Galderma – Advisory Board(Honoraria); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Fees); Horizon Pharma, Inc. – Consultant(Fees); Incyte Corporation – Advisory Board(Honoraria), Consultant(Fees), Data Safety Monitoring Board(Fees), Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Consultant(Fees); Leo Pharma – Advisory Board(Honoraria); Merck – Consultant (1099 relationship)(Fees); Pfizer Inc. – Advisory Board(Fees), Advisory Board(Honoraria), Consultant(Fees), Investigator(Fees), Speaker(Honoraria); Q32 Bio Inc. – Consultant (1099 relationship)(Fees); Regeneron – Speaker(Honoraria); Sanofi Genzyme – Speaker(Honoraria); Soterios Pharma – Consultant (1099 relationship)(Fees); Sun Pharmaceutical Industries Ltd. – Consultant(Fees), Investigator(Fees); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); TWi Biotechnology, Inc. – Consultant(Fees);
Michael S. Kolodney, MD, PhD
No financial relationships exist with ineligible companies.
Jenny Lai, PhD
No financial relationships exist with ineligible companies.
Bella Lee
No financial relationships exist with ineligible companies.
Eden Louise Pappo Lake, MD, FAAD
No financial relationships exist with ineligible companies.
Milton Rodríguez-Zúñiga, MD
Boehringer Ingelheim – Employee (w-2 relationship)(Salary); Johnson & Johnson Innovative Medicine – Employee (w-2 relationship)(Salary);
Emily S Ruiz, MD, FAAD
Almirall – Consultant (1099 relationship)(Fees); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Consultant (1099 relationship)(Fees);
leonie schelke
Allergan Aesthetics – Speaker(Honoraria); Cutaneous BV – Founder(No Compensation Received);
Divya Srivastava, MD, FAAD
Spruce – Employee(Stock Options);
Wendi E. Wohltmann, MD, FAAD
No financial relationships exist with ineligible companies.
Katherine Wojcik
No financial relationships exist with ineligible companies.
Sarah Woodside, MD
No financial relationships exist with ineligible companies.
Zachary A. Zinn, MD, FAAD
No financial relationships exist with ineligible companies.